PETS · Petmed Express Inc
The latest filing states the doubt was alleviated.
“During the three months ended June 30, 2026, management's assessment identified certain conditions and events that, when considered in the aggregate, raised substantial doubt about the Company's ability to continue as a going concern. ... As of the issuance of these financials, management has concluded that substantial doubt about the Company's ability to continue as a going concern for the next twelve months is alleviated by these plans.”View the 10-Q filed Aug 13, 2026
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| new customers | 70,000 | the quarter ended June 30, 2026 | — |
| Adjusted EBITDA non-GAAP | -$15.4M | fiscal year 2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Pharmaceutical Retailers — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PETS
this stock
Petmed Express Inc
|
$42.95M | -43.0% | +9.9% | — | 3.0% |
|
RTEZ
REST EZ Inc.
|
$1.93B | — | -100.0% | — | 0.0% |
|
HITI
High Tide Inc.
|
$205.00M | -11.3% | — | — | 1.0% |
|
BHIC
BioScience Health Innovations, Inc.
|
$52.77M | — | +208.3% | — | 0.0% |
|
SHFH
Scientist Home Future Health Ltd
|
$45.06M | — | — | — | — |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PETS | -7.8% | -7.4% | -36.6% | -6.4% | -43.0% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -8.2% | -11.8% | -50.4% | -10.3% | -56.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.